Back to Search
Start Over
From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer.
- Source :
-
ESMO open [ESMO Open] 2019 Sep 08; Vol. 4 (5), pp. e000548. Date of Electronic Publication: 2019 Sep 08 (Print Publication: 2019). - Publication Year :
- 2019
-
Abstract
- Competing Interests: Competing interests: RP has received speaker's fees from AstraZeneca and Boehringer Ingelheim, honoraria for Advisory Boards from Boehringer Ingelheim, Jansen Oncology as well as Takeda, and honoraria for Data Monitoring Committee participation from Genmab, Gedeon Richter, Merck Sharp Dohme and Regeneron. MF has received speaker’s fees and honoraria for Advisory Boards from AstraZeneca, Bayer, Biomedica, Boehringer Ingelheim, Eli Lilly, Merck, Myriad Genetics, Pfizer, and Roche.
Details
- Language :
- English
- ISSN :
- 2059-7029
- Volume :
- 4
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- ESMO open
- Publication Type :
- Editorial & Opinion
- Accession number :
- 31555485
- Full Text :
- https://doi.org/10.1136/esmoopen-2019-000548